These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34311397)

  • 21. From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug.
    Lock EA; Ellis MK; Gaskin P; Robinson M; Auton TR; Provan WM; Smith LL; Prisbylla MP; Mutter LC; Lee DL
    J Inherit Metab Dis; 1998 Aug; 21(5):498-506. PubMed ID: 9728330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nitisinone causes acquired tyrosinosis in alkaptonuria.
    Khedr M; Cooper MS; Hughes AT; Milan AM; Davison AS; Norman BP; Sutherland H; Jarvis JC; Fitzgerald R; Markinson L; Psarelli EE; Ghane P; Deutz NEP; Gallagher JA; Ranganath LR
    J Inherit Metab Dis; 2020 Sep; 43(5):1014-1023. PubMed ID: 32083330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Laboratory monitoring of patients with hereditary tyrosinemia type I.
    Schultz MJ; Netzel BC; Singh RH; Pino GB; Gavrilov DK; Oglesbee D; Raymond KM; Rinaldo P; Tortorelli S; Smith WE; Matern D
    Mol Genet Metab; 2020 Aug; 130(4):247-254. PubMed ID: 32546364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day.
    Kienstra NS; van Reemst HE; van Ginkel WG; Daly A; van Dam E; MacDonald A; Burgerhof JGM; de Blaauw P; McKiernan PJ; Heiner-Fokkema MR; van Spronsen FJ
    J Inherit Metab Dis; 2018 Mar; 41(2):181-186. PubMed ID: 29170874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simple and fast quantification of nitisone (NTBC) using liquid chromatography-tandem mass spectrometry method in plasma of tyrosinemia type 1 patients.
    Davit-Spraul A; Romdhane H; Poggi-Bach J
    J Chromatogr Sci; 2012 May; 50(5):446-9. PubMed ID: 22511487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liquid chromatography tandem mass spectrometry method for the quantitation of NTBC (2-(nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione) in plasma of tyrosinemia type 1 patients.
    Herebian D; Spiekerkötter U; Lamshöft M; Thimm E; Laryea M; Mayatepek E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 May; 877(14-15):1453-9. PubMed ID: 19345648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry.
    Hughes AT; Milan AM; Davison AS; Christensen P; Ross G; Gallagher JA; Dutton JJ; Ranganath LR
    Ann Clin Biochem; 2015 Sep; 52(Pt 5):597-605. PubMed ID: 25628464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical and behavioural profile of NTBC treated Tyrosinemie type 1 mice.
    van Ginkel WG; Winn SR; Dudley S; Krenik D; Perez R; Rimann N; Thöny B; Raber J; Harding CO
    Mol Genet Metab; 2022; 137(1-2):9-17. PubMed ID: 35868243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evolution of a case of tyrosinemia type I treated with NTBC].
    Ros Viladoms J; Vilaseca Buscà MA; Lambruschini Ferri N; Mas Comas A; González Pascual E; Holme E
    An Esp Pediatr; 2001 Mar; 54(3):305-9. PubMed ID: 11262262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).
    Holme E; Lindstedt S
    J Inherit Metab Dis; 1998 Aug; 21(5):507-17. PubMed ID: 9728331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. D-serine-induced nephrotoxicity: possible interaction with tyrosine metabolism.
    Williams RE; Lock EA
    Toxicology; 2004 Sep; 201(1-3):231-8. PubMed ID: 15297036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nitisinone-Induced Keratopathy in Alkaptonuria: A Challenging Diagnosis Despite Clinical Suspicion.
    White A; C Tchan M
    JIMD Rep; 2018; 40():7-9. PubMed ID: 28879639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria.
    Milan AM; Hughes AT; Davison AS; Khedr M; Rovensky J; Psarelli EE; Cox TF; Rhodes NP; Gallagher JA; Ranganath LR
    Sci Rep; 2019 Jul; 9(1):10024. PubMed ID: 31296884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment adherence in tyrosinemia type 1 patients.
    González-Lamuño D; Sánchez-Pintos P; Andrade F; Couce ML; Aldámiz-Echevarría L
    Orphanet J Rare Dis; 2021 Jun; 16(1):256. PubMed ID: 34082789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Favorable outcome of treatment with NTBC of acute liver insufficiency disclosing hereditary tyrosinemia type I].
    Barkaoui E; Debray D; Habès D; Ogier H; Bernard O
    Arch Pediatr; 1999 May; 6(5):540-4. PubMed ID: 10370811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological rescue of the 14CoS/14CoS mouse: hepatocyte apoptosis is likely caused by endogenous oxidative stress.
    Dieter MZ; Freshwater SL; Miller ML; Shertzer HG; Dalton TP; Nebert DW
    Free Radic Biol Med; 2003 Aug; 35(4):351-67. PubMed ID: 12899938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perturbations of tyrosine metabolism promote the indolepyruvate pathway via tryptophan in host and microbiome.
    Gertsman I; Gangoiti JA; Nyhan WL; Barshop BA
    Mol Genet Metab; 2015 Mar; 114(3):431-7. PubMed ID: 25680927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of NTBC in serum samples from patients with hereditary tyrosinemia type I by capillary electrophoresis.
    Cansever MS; Aktuğlu-Zeybek AC; Erim FB
    Talanta; 2010 Mar; 80(5):1846-8. PubMed ID: 20152421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting tyrosinaemia: a mathematical model of 4-hydroxyphenylpyruvate dioxygenase inhibition by nitisinone in rats.
    Ward JP; Dunster JL; Derks G; Mistry P; Salazar JD
    Math Med Biol; 2017 Sep; 34(3):335-390. PubMed ID: 27305933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Corneal opacities associated with NTBC treatment.
    Ahmad S; Teckman JH; Lueder GT
    Am J Ophthalmol; 2002 Aug; 134(2):266-8. PubMed ID: 12140036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.